Belluscura , is a pioneering medical devices firm focused on lightweight/portable oxygen concentrators (POCs) & associate enrichment technology.
Today the business announced its 5th US distributor, a large online retailer based in Colorado & Georgia - having served cumulatively >100,000 customers.
Importantly, this means BELL has already [ie >2 months early] exceeded the initial commercial launch target for its ground breaking X-PLO₂R POC. No mean feat given the disruption to global supply chains.
CEO Bob Rauker adding: "Demand has been excellent - & over the past 5 months, Belluscura has been able to put in place distribution agreements that cover the majority of North America from the East to West coast. In addition, the Company is receiving interest from overseas distributors. We will update shareholders with expected unit deliveries for 2021 (consensus at 150) and 2022 (2,000 & 12,000 for 2023) in the near future."
Indeed by 2023, house broker Dowgate Capital Limited reckon #BELL will be profitable ($1.1m EBITDA) on sales of $19.8m with closing net cash of $9m vs $18.5m as at Dec'21.